This article synthesizes the current landscape, challenges, and future directions for deploying Artificial Intelligence (AI) models in clinical practice and drug development.
This article provides a comprehensive overview of deep learning architectures revolutionizing medical image analysis.
This article provides a comprehensive analysis of Next-Generation Sequencing (NGS) versus traditional methods for detecting BRAF, EGFR, and KRAS mutations in oncology.
The management of Variants of Uncertain Significance (VUS) is a central challenge in next-generation sequencing (NGS), directly impacting diagnostic clarity, drug development pipelines, and clinical trial design.
This article provides a comprehensive overview of the transformative role of single-cell sequencing (SCS) in oncology.
Next-generation sequencing (NGS) has revolutionized the identification of hereditary cancer syndromes, moving genetic testing beyond single-gene analyses to comprehensive multigene panels.
This article provides a comprehensive overview of Whole Exome Sequencing (WES) and its transformative role in modern cancer research and therapeutic development.
This article provides a comprehensive analysis of sensitivity optimization for early-stage cancer detection models, a critical frontier in oncology.
The integration of Artificial Intelligence (AI) into oncology holds transformative potential for diagnostics, treatment personalization, and drug discovery.
The integration of hybrid deep learning (DL) architectures is revolutionizing genomic analysis, offering unprecedented accuracy in variant calling, tumor subtyping, and biomarker discovery.